ADC Therapeutics

130 articles with ADC Therapeutics

• ADC Therapeutics Announces Abstracts to be Presented at the European Hematology Association 2022 Hybrid Congress

  5/12/2022

  ADC Therapeutics SA (NYSE: ADCT), announced today that results from the pivotal Phase 2 clinical trial of camidanlumab tesirine (Cami) in patients with relapsed or refractory Hodgkin lymphoma have been accepted for an oral presentation.

• 

  ADC, Adimab and Longeveron Begin New Leadership Chapters

  5/10/2022

  Three life sciences companies, ADC Therapeutics, Longeveron and Adimab, are undertaking leadership transitions with the announcements of new chief executive officers.

• ADC Therapeutics Reports First Quarter 2022 Financial Results and Provides Business Updates

  5/9/2022

  ADC Therapeutics SA today reported financial results for the first quarter ended March 31, 2022 and provided business updates.

• ADC Therapeutics Announces CEO Transition

  5/9/2022

  ADC Therapeutics SA announced that Chris Martin, DPhil, has stepped down as Chief Executive Officer.

• ADC Therapeutics to Present at the BofA Securities 2022 Healthcare Conference

  5/4/2022

  ADC Therapeutics SA announced today that its executives will be participating in a fireside chat at the BofA Securities 2022 Healthcare Conference on Tuesday, May 10, 2022, at 1:40 pm ET.

• ADC Therapeutics to Host First Quarter 2022 Financial Results Conference Call on May 9, 2022

  5/3/2022

  ADC Therapeutics to Host First Quarter 2022 Financial Results Conference Call on May 9, 2022.

• ADC Therapeutics Receives Permanent J-Code for ZYNLONTA® (J9359) from U.S. Centers for Medicare & Medicaid Services

  4/4/2022

  ADC Therapeutics SA announced today that a permanent J-code, J9359, has been issued for ZYNLONTA® by the U.S. Centers for Medicare & Medicaid Services (CMS) effective as of April 1, 2022.

• ADC Therapeutics Releases its Annual Report on Form 20-F for the Fiscal Year Ended December 31, 2021

  3/17/2022

  ADC Therapeutics SA today announced its Annual Report on Form 20-F for the fiscal year ended December 31, 2021.

• ADC Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates

  3/3/2022

  ADC Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Business Updates.

• ADC Therapeutics to Participate in Cowen’s 42nd Annual Health Care Conference

  3/1/2022

  ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, announced today that Chris Martin, DPhil, Chief Executive Officer, will participate in a fireside chat at Cowen’s virtual 42nd Annual Health Care Conference.

• ADC Therapeutics to Host Fourth Quarter and Year-End 2021 Financial Results Conference Call on March 3, 2022

  2/24/2022

  ADC Therapeutics SA today announced that it will host a conference call and live webcast on Thursday, March 3, 2022 at 8:30 a.m. ET to report financial results for the fourth quarter and year-end 2021 and provide business updates.

• ADC Therapeutics Releases its Inaugural Environmental, Social and Governance Report

  2/17/2022

  ADC Therapeutics SA today unveiled its first Environmental, Social and Governance (ESG) report detailing the Company’s focus on patient care and sustainable innovation.

• ADC Therapeutics Highlights its Proprietary ADC Platform and Solid Tumor Pipeline

  2/8/2022

  ADC Therapeutics SA today will provide insight into its ADC platform and solid tumor pipeline during a live webcast from 9:00 to 11:00 a.m. EST.

• ADC Therapeutics to Participate in Guggenheim Oncology Conference

  2/2/2022

  ADC Therapeutics SA announced that Chris Martin, PhD, Chief Executive Officer, will participate in a fireside chat at the virtual Guggenheim Oncology Conference on Wednesday, February 9th at 9:30 a.m. EST.

• ADC Therapeutics to Host Webcast Highlighting its ADC Platform and Solid Tumor Pipeline on February 8, 2022

  1/20/2022

  ADC Therapeutics SA today announced it will host a webcast highlighting its ADC platform and solid tumor pipeline on Tuesday, February 8, from 9:00 to 11:00 a.m. ET.

• ADC Therapeutics Announces Exclusive License with Mitsubishi Tanabe Pharma Corporation to Develop and Commercialize ZYNLONTA® (loncastuximab tesirine-lpyl) in Japan

  1/18/2022

  ADC Therapeutics SA announced it has entered an exclusive license agreement with Mitsubishi Tanabe Pharma Corporation for the development and commercialization of ZYNLONTA® for all hematologic and solid tumor indications in Japan.

• ADC Therapeutics to Participate in the Jefferies London Healthcare Conference

  11/9/2021

  ADC Therapeutics SA announced today that Chris Martin, PhD, Chief Executive Officer, will participate in a fireside chat at the Jefferies London Healthcare Conference on Tuesday, November 16th at 11:20 a.m. GMT / 6:20 a.m. EST.

• ADC Therapeutics Announces Abstracts to be Presented at the 63rd ASH Annual Meeting

  11/4/2021

  ADC Therapeutics Announces Abstracts to be Presented at the 63rd ASH Annual Meeting

• ADC Therapeutics Reports Third Quarter 2021 Financial Results and Provides Business Updates

  11/2/2021

  ZYNLONTA ® (loncastuximab tesirine-lpyl) third quarter 2021 net sales of $13.1 million

• ADC Therapeutics Announces Validation of its Marketing Authorization Application by the European Medicines Agency for ZYNLONTA®

  10/29/2021

  ADC Therapeutics SA today announced its Marketing Authorization Application (MAA) for ZYNLONTA®, a CD19-targeted ADC for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), has been validated by the European Medicines Agency (EMA).